Navigation Links
Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against 2012 Nobel Laureate Dr. Yamanaka for Deception
Date:5/15/2013

lication. However, this technology that allows "regeneration of damaged organs" has been hindered from benefiting the general public due to the scientific scam by Dr. Yamanaka, depriving the chances of tens of thousands of patients for getting access to innovative science and technology for cures.

The scientific route of "developing drugs to regenerate damaged organs" has been labeled one of the nation's main topics of focus, and was also discussed by president Obama in his 2013 State of the Union Address, where he stated "Now, if we want to make the best products, we also have to invest in the best ideas. Every dollar we invested to map the human genome returned $140 to our economy. Every dollar. Today, our scientists are mapping the human brain to unlock the answers to Alzheimer's. We're developing drugs to regenerate damaged organs, devising new materials to make batteries 10 times more powerful. Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the space race. We need to make those investments."

Dr. Xu is thankful for the Obama administration's acknowledgement of this vital area of organ regeneration, and feels that this direction is a blessing for Americans and people worldwide.

Please contact Jane Westgate 336.608.4439 or Cheryl Riley 703.683.1798. The Plaintiff is represented by the Ardent Law Group in California.


'/>"/>
SOURCE Mebo International; Ardent Law Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. Rongxiang Xu, Owner of Patented Technology to Regenerate Damaged Organs, Announces Lawsuit Against 2012 Nobel Laureate Dr. Shinya Yamanaka
2. PharmaDirections is Co-inventor on Second Issued Formulation Patent Entitled “Layered Pharmaceutical Formulations”
3. First patent issues on TAL effector technology
4. Wysebridge Patent Bar Review Supports the National Foundation for Celiac Awareness (NFCA) During Celiac Awareness Month
5. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
6. mPhase Technologies Receives Issue Notification Of Key Patent
7. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
8. Stemedica Issued U.S. Patent For Ectodermal Stem Cells
9. Wysebridge Patent Bar Review Launches America Invents Act (AIA) Study Suite
10. Cancer Advances Announces Issuance of Three New Patents to Its Suite of Gastrin Inhibitor Products
11. DuPont Receives ‘Patents for Humanity’ Award for Groundbreaking Research to Improve Nutritional Profile of Staple Crop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and exhibition ... at Double Tree by Hilton Beijing, China is all ... & Bioanalytical research methods only to facilitate improved living ... Dr. Srinubabu Gedela, MD of OMICS Group Inc has ... one in bringing a unique and international mix of ...
(Date:7/10/2014)... 10, 2014  Kainos Capital, a firm specializing in ... that it has acquired the Slim-Fast brand from Unilever. ... Terms of the transaction were not disclosed. ... business that markets ready-to-drink shakes, powders, bars and snacks ... and in the United Kingdom ...
(Date:7/10/2014)... the fight against terrorism with the creation of a ... the use of light and special glass fibres. , ... Chemical , the researchers describe a novel optical fibre ... as 6.3 ppm (parts per million). It requires an ... explosives detection has involved looking for metals that encase ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2
... , COPENHAGEN, June 4 ... an inhibitor of HIF-1alpha, jointly developed by,Enzon Pharmaceuticals and ... signs of clinical benefit in previously treated cancer patients ... solid,tumors and lymphoma. The study data, which was presented ...
... June 4 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... , , 8th ... Eastern Time at the New York Palace Hotel in New York City. , ... June 18, 2009 at 1:30 p.m. Eastern Time at the Mandarin Oriental Hotel ...
... Austria, June 4 EUCODIS Bioscience, a company,developing ... announced today that it has successfully launched its ... by EUCODIS,Bioscience and can be supplied in a ... antibiotics manufacturers to improve,quality control, to the diagnostics ...
Cached Biology Technology:LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 2LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 3Optimer Pharmaceuticals to Present at June 2009 Investor Conferences 2EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries 2
(Date:7/11/2014)... near the City of Entiat on Tuesday, July 8, ... quickly grew to over 1,000 acres by evening. Three ... under investigation by the Washington Department of Natural Resources. ... resources in developing fire control strategies and tactics. Other ... Department of Natural Resources, (WA DNR), Bureau of Land ...
(Date:7/11/2014)... Institute of Standards and Technology (NIST) need a ... they often prove that necessity is truly the ... for M. Lorna De Leoz and Stephen Stein, ... glycomics. Glycomics is the study of the abundant, ... to proteins and lipids and influence cellular processes, ...
(Date:7/11/2014)... Researchers from Ume University, Sweden, have explored two ... the reaction sequence leading to the formation of ... been published in the scientific journal Nature ... improving present day synthetic catalysts for water oxidation, ... devices for the direct storage of solar energy ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... Steven Chu announced today the winners of the 2009 E.O. ... supporting the Department of Energy and its missions. The ... citation and $50,000. Winners will be honored at ... made by these researchers to advance the national, economic and ...
... short-term, seasonal exposure to pesticides in rivers and basins ... populations. In addition to the widespread deterioration of salmon ... pesticides may further inhibit the recovery of threatened or ... to restore Pacific salmon habitats in an effort to ...
... , , SUNNYVALE, Calif., Dec. 1 GestureTek ... 3.0 - a turnkey, portable, plug and play interactive ... promotions. GestureTek is the inventor and holder of dozens ... display, presentation and entertainment systems. , Guaranteed for quality, ...
Cached Biology News:Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners 2Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
HIV-1 TAT (vN-21)...
Request Info...
Request Info...
Biology Products: